Volume 14, Number 7—July 2008
Letter
Importation of West Nile Virus Infection from Nicaragua to Spain
Begoña Monge Maillo*, Rogelio López-Vélez*
, Francesca F. Norman*, Fernando de Ory†, María Paz Sanchez-Seco†, and Cesare Giovanni Fedele†
, Francesca F. Norman*, Fernando de Ory†, María Paz Sanchez-Seco†, and Cesare Giovanni Fedele†
Table
Serologic results for antibodies to West Nile virus (WNV), dengue virus (DV), and tick-borne encephalitis virus (TBEV)*
| Sample/ d after onset | WNV |
DV ELISA |
TBEV ELISA |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELISA |
PRNT |
||||||||||||
| IgG† | IgG‡ | IT-IgG§ | IgM† | Ab‡ | IT Ab¶ | IgG† | IgM† | IgG† | IgM† | ||||
| S1/13 | 3.5 | 65,000 | 3.54 | 3.6 | 256 | 7.0 | 4.8 | 0.3 | 59.5 | 0.1 | |||
| CSF/13 | 4,000 | Pos# | 32 | ||||||||||
| S2/160 | 3.2 | 16,000 | 0.8 | 64 | 4.5 | 0.2 | 27 | 0.1 | |||||
*PRNT, plaque reduction neutralization assay; Ig, immunoglobulin; Ab, antibodies; IT, intrathecal; S1, first serum sample, obtained 13 days after onset of symptoms; CSF, cerebrospinal fluid; Pos, positive; S2, second serum sample, obtained 160 days after onset of symptoms.
†Results expressed as the ratio of sample absorbance to cutoff value (positive >1.0).
‡Titer.
§IT production of WNV IgG (ELISA).
¶IT production of WNV antibodies (PRNT).
#CSF tested diluted 1:2.
Page created: July 12, 2010
Page updated: July 12, 2010
Page reviewed: July 12, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
Content Credential